Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2009

Cetero Enhances Early-Stage Facility in Texas

  • Cetero Research says that it has expanded its San Antonio, TX, operations. The site has a new 100-bed facility designed to run clinical pharmacology studies in healthy, diabetic, and obese participants.

    The site has conducted clinical studies for more than 25 years, according to Sherwyn Schwartz, M.D., CEO of Cetero’s San Antonio facility. “One notable expansion is increased capacity to perform euglycemic and insulin-clamp studies. These specialized studies are ideal for establishing proof-of-concept for novel compounds or even comparing compounds to show superiority or equivalence.”

    The facility is located on the Christus Santa Rosa Medical Campus and adjacent to one of the largest endocrinology practices in the country that sees more than 6,500 patients per month. In addition to a large database of normal healthy participants, type 1 and type 2 diabetics, and obese patients, Cetero also has access to patients with hypogonadism, neuropathy, osteoporosis, and erectile dysfunction.

    ---

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »